NASDAQ:QDEL - Quidel Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $65.43 +1.13 (+1.76 %) (As of 02/17/2019 11:44 AM ET)Previous Close$65.43Today's Range$64.23 - $66.4452-Week Range$41.97 - $77.63Volume348,734 shsAverage Volume278,320 shsMarket Capitalization$2.57 billionP/E Ratio23.20Dividend YieldN/ABeta1.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California. Receive QDEL News and Ratings via Email Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:QDEL Previous Symbol CUSIP74838J10 Webwww.quidel.com Phone858-552-1100Debt Debt-to-Equity Ratio0.21 Current Ratio1.26 Quick Ratio0.86Price-To-Earnings Trailing P/E Ratio23.20 Forward P/E Ratio24.41 P/E Growth0.91 Sales & Book Value Annual Sales$522.28 million Price / Sales4.93 Cash Flow$1.1657 per share Price / Cash Flow56.13 Book Value$6.68 per share Price / Book9.79Profitability EPS (Most Recent Fiscal Year)$2.82 Net Income$-8,160,000.00 Net Margins14.20% Return on Equity33.10% Return on Assets14.86%Miscellaneous Employees1,193 Outstanding Shares39,337,000Market Cap$2.57 billion OptionableOptionable Quidel (NASDAQ:QDEL) Frequently Asked Questions What is Quidel's stock symbol? Quidel trades on the NASDAQ under the ticker symbol "QDEL." How were Quidel's earnings last quarter? Quidel Co. (NASDAQ:QDEL) posted its earnings results on Wednesday, February, 13th. The company reported $0.75 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.54 by $0.21. The business earned $132.59 million during the quarter, compared to analysts' expectations of $132.26 million. Quidel had a return on equity of 33.10% and a net margin of 14.20%. The firm's revenue was up 15.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 earnings per share. View Quidel's Earnings History. When is Quidel's next earnings date? Quidel is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Quidel. What price target have analysts set for QDEL? 7 analysts have issued 12 month price targets for Quidel's stock. Their forecasts range from $63.00 to $80.00. On average, they expect Quidel's share price to reach $72.20 in the next twelve months. This suggests a possible upside of 10.3% from the stock's current price. View Analyst Price Targets for Quidel. What is the consensus analysts' recommendation for Quidel? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 hold rating, 4 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quidel. Has Quidel been receiving favorable news coverage? Headlines about QDEL stock have trended negative on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Quidel earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Quidel's key competitors? Some companies that are related to Quidel include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Quotient (QTNT), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML), ImmuCell (ICCC) and Riot Blockchain (RIOT). Who are Quidel's key executives? Quidel's management team includes the folowing people: Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)Mr. Randall J. Steward, Chief Financial Officer (Age 65)Mr. Robert J. Bujarski, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 51)Dr. Werner Kroll, Sr. VP of R&D (Age 62)Mr. Edward Keith Russell, Sr. VP of North America Commercial Operations (Age 51) Who are Quidel's major shareholders? Quidel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.86%), Macquarie Group Ltd. (2.42%), Dimensional Fund Advisors LP (2.19%), New York State Common Retirement Fund (1.90%), Eagle Asset Management Inc. (1.60%) and Gamco Investors INC. ET AL (1.29%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Jack W Schuler, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel. Which institutional investors are selling Quidel stock? QDEL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bank of New York Mellon Corp, Two Sigma Investments LP, Gotham Asset Management LLC, First Trust Advisors LP, Chartwell Investment Partners LLC, Crown Advisors Management Inc. and Eagle Asset Management Inc.. Company insiders that have sold Quidel company stock in the last year include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Kenneth F Buechler, Mary Lake Ph D Polan, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski and Thomas D Brown. View Insider Buying and Selling for Quidel. Which institutional investors are buying Quidel stock? QDEL stock was acquired by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Bellevue Group AG, Gagnon Securities LLC, Massachusetts Financial Services Co. MA, SG Americas Securities LLC, Geode Capital Management LLC, Bank of Montreal Can and Martingale Asset Management L P. View Insider Buying and Selling for Quidel. How do I buy shares of Quidel? Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quidel's stock price today? One share of QDEL stock can currently be purchased for approximately $65.43. How big of a company is Quidel? Quidel has a market capitalization of $2.57 billion and generates $522.28 million in revenue each year. The company earns $-8,160,000.00 in net income (profit) each year or $2.82 on an earnings per share basis. Quidel employs 1,193 workers across the globe. What is Quidel's official website? The official website for Quidel is http://www.quidel.com. How can I contact Quidel? Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected] MarketBeat Community Rating for Quidel (NASDAQ QDEL)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 315 (Vote Outperform)Underperform Votes: 272 (Vote Underperform)Total Votes: 587MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: What is the Dow Jones Industrial Average (DJIA)?